ExodusPoint Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

ExodusPoint Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,327	Closed	-$544K	–	2224
2022 Q4	$544K	Sell	14,327 -19,267	-57%	-$663K	0.01%	1139
2022 Q3	$844K	Sell	33,594 -88,156	-72%	-$2.44M	0.01%	1176
2022 Q2	$3.7M	Buy	121,750 +106,927	+721%	+$3.19M	0.05%	516
2022 Q1	$486K	Sell	14,823 -50,735	-77%	-$1.51M	0.01%	1556
2021 Q4	$1.73M	Buy	+65,558	New	+$5.07M	0.02%	817
2021 Q2	–	Sell	-22,123	Closed	-$2.21M	–	2949
2021 Q1	$2.21M	Buy	22,123 +16,479	+292%	+$1.92M	0.03%	538
2020 Q4	$698K	Buy	+5,644	New	+$742K	0.01%	1051
2020 Q3	–	Sell	-15,298	Closed	-$2.39M	–	2350
2020 Q2	$2.39M	Buy	15,298 +10,919	+249%	+$1.66M	0.06%	361
2020 Q1	$632K	Sell	4,379 -3,268	-43%	-$631K	0.03%	417
2019 Q4	$1.56M	Buy	7,647 +4,647	+155%	+$848K	0.03%	406
2019 Q3	$241K	Buy	+3,000	New	+$255K	0.01%	1020

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's RETA Position: Q1 2023 in Review

ExodusPoint Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 14,327 shares — an estimated $544K sold.

ExodusPoint Capital Management first reported a position in RETA in Q3 2019 and held it in 11 quarters. The position peaked at $3.7M in Q2 2022. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

ExodusPoint Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 14,327 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $544K.
ExodusPoint Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 11 quarters.
ExodusPoint Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.7M in Q2 2022.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.